Lode Resources may have found more than antimony at Montezuma. What does it mean for ASX:LDR investors?
Read More Pharma Industry News How VERVE-102 could accelerate the transition from chronic lipid therapy to genomic medicine Could VERVE-102 shift cholesterol treatment from chronic therapy to one-time gene editing? Explore Eli Lilly and Company’s genomic medicine strategy. bySoujanya RaviMay 27, 2026